Prespecified subgroup (secondary) analysis of 3655 patients with diabetes but no known significant atherosclerosis: evolocumab vs placebo on statins cut 3-P MACE (5-year KM estimate 5.0% vs 7.1%; HR 0.69) and 4-P MACE (7.6% vs 10.5%; HR 0.69).
RCTn = 3,655
Marston et al. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial